Drug Details
General Information of the Drug (ID: DR6690) | ||||
---|---|---|---|---|
Name |
Streptomycin
|
|||
Synonyms |
streptomycin; 57-92-1; Streptomycin A; Strepcen; Gerox; Streptomycine; Streptomycin sulphate; Chemform; Streptomycin sulfate; CHEBI:17076; UNII-Y45QSO73OB; Estreptomicina; NSC-14083; Streptomycin A sulfate; Y45QSO73OB; 2,4-Diguanidino-3,5,6-trihydroxycyclohexyl 5-deoxy-2-O-(2-deoxy-2-methylamino-alpha-L-glucopyranosyl)-3-C-formyl-beta-L-lyxopentanofuranoside; 2-[(1R,2R,3S,4R,5R,6S)-3-(diaminomethylideneamino)-4-[(2R,3R,4R,5S)-3-[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy-2,5,6-trihydroxycyclohexyl]guanidine; Agrimycin; Agrept; Neodiestreptopab; Streptomicina; Streptomycinum; Streptomyzin; Hokko-mycin; [2-deoxy-2-(dimethylamino)-alpha-L-glucopyranosyl]-(1->2)-[5-deoxy-3-C-formyl-alpha-L-lyxofuranosyl]-(1->4)-{N',N'''-[(1,3,5/2,4,6)-2,4,5,6-tetrahydroxycyclohexane-1,3-diyl]diguanidine}; 1-[(1S,2R,3R,4S,5R,6R)-3-carbamimidamido-6-{[(2R,3R,4R,5S)-3-{[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy}-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy}-2,4,5-trihydroxycyclohexyl]guanidine; N,N'''-[(1R,2R,3S,4R,5R,6S)-4-({5-deoxy-2-O-[2-deoxy-2-(methylamino)-alpha-L-glucopyranosyl]-3-C-formyl-alpha-L-lyxofuranosyl}oxy)-2,5,6-trihydroxycyclohexane-1,3-diyl]diguanidine; SRY; Streptomycin Sesquisulfate Hydrate; Caswell No. 804; Streptomyzin [German]; Streptomicina [Italian]; NCGC00159339-02; Streptomycin [INN:BAN]; Streptomycin, Sulfate Salt; streomycin; Geroxeg; Estreptomicina [INN-Spanish]; CCRIS 5730; HSDB 1768; Streptomycin,(S); 1-[(1S,2R,3R,4S,5R,6R)-2-[(2R,3R,4R,5S)-3-[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)tetrahydropyran-2-yl]oxy-4-formyl-4-hydroxy-5-methyl-tetrahydrofuran-2-yl]oxy-5-guanidino-3,4,6-trihydroxy-cyclohexyl]guanidine; Streptomycin (TN); EINECS 200-355-3; Streptomycin (INN); EPA Pesticide Chemical Code 006306; Liposomal Streptomycin; NSC14083; BRN 0074498; Epitope ID:224553; SCHEMBL3276; 4-18-00-07540 (Beilstein Handbook Reference); D-Streptamine, O-2-deoxy-2-(methylamino)-alpha-L-glucopyranosyl-(1-2)-O-5-deoxy-3-C-formyl-alpha-L-lyxofuranosyl-(1-4)-N,N'-bis(aminoiminomethyl)-; CHEMBL372795; DTXSID4023597; GTPL10923; Streptomycin Sesquisulphate Hydrate; ZINC8214681; BDBM50103513; MFCD00072108; AKOS015969759; AM84920; DB01082; AS-35042; tetrahydro-2H-pyran-2-yloxy)-4-formyl-4; 280-EP2269990A1; 280-EP2270001A1; 280-EP2270006A1; 280-EP2270008A1; 280-EP2270014A1; 280-EP2272832A1; 280-EP2275420A1; 280-EP2275422A1; 280-EP2277861A1; 280-EP2277876A1; 280-EP2277880A1; 280-EP2277898A2; 280-EP2281563A1; 280-EP2281824A1; 280-EP2284154A1; 280-EP2284169A1; 280-EP2284171A1; 280-EP2284172A1; 280-EP2286812A1; 280-EP2287161A1; 280-EP2287162A1; 280-EP2289876A1; 280-EP2289882A1; 280-EP2289886A1; 280-EP2289892A1; 280-EP2289893A1; 280-EP2292088A1; 280-EP2292592A1; 280-EP2292608A1; 280-EP2292610A1; 280-EP2292612A2; 280-EP2292614A1; 280-EP2292617A1; 280-EP2295055A2; 280-EP2295402A2; 280-EP2295411A1; 280-EP2295416A2; 280-EP2295417A1; 280-EP2295434A2; 280-EP2298748A2; 280-EP2301536A1; 280-EP2301538A1; 280-EP2301544A1; 280-EP2301940A1; 280-EP2305033A1; 280-EP2305652A2; 280-EP2305658A1; 280-EP2305662A1; 280-EP2305684A1; 280-EP2305688A1; 280-EP2308562A2; 280-EP2308844A2; 280-EP2308845A2; 280-EP2308846A2; 280-EP2308855A1; 280-EP2308857A1; 280-EP2308872A1; 280-EP2308960A1; 280-EP2311453A1; 280-EP2311455A1; 280-EP2311494A1; 280-EP2311806A2; 280-EP2311836A1; 280-EP2314583A1; 280-EP2316452A1; 280-EP2316459A1; 280-EP2316829A1; 280-EP2316832A1; 280-EP2316833A1; 280-EP2316937A1; 280-EP2371811A2; C00413; D08531; 3-((2S,3S,4S,5R,6S)-4,5-dihydroxy-6; AB00443813_02; 057S921; 2,5,6-trihydroxycyclohexane-1,3-diyl)diguanidine; Q192717; BRD-K07166362-330-02-8; 1,-((1R,2R,3S,4R,5R,6S)-4-((2R,3R,4R,5S)-; 2,4-Diguanidino-3,5,6-trihydroxycyclohexyl 5-deoxy-2-O-(2-deoxy-2-methylamino-alpha-glucopyranosyl)-3-formylpentofuranoside; D-Streptamine, O-2-deoxy-2-(methylamino)-.alpha.-L-glucopyranosyl-(1->2)-O-5-deoxy-3-C-formyl-.alpha.-L-lyxofuranosyl-(1->4)-N,N'-bis(aminoiminomethyl)-; D-Streptamine, O-2-deoxy-2-(methylamino)-alpha-L-glucopyranosyl-(1.fwdarw.2)-O-5-deoxy-3-C-formyl-alpha-L-lyxofuranosyl-(1.fwdarw.4)-N,N'-bis(aminoiminomethyl)-; N,N'''-[(1R,2R,3S,4R,5R,6S)-4-{5-deoxy-2-O-[2-deoxy-2-(methylamino)-alpha-L-glucopyranosyl]-3-C-formyl-alpha-L-lyxofuranosyloxy}-2,5,6-trihydroxycyclohexane-1,3-diyl]diguanidine; O-2-Deoxy-2-(methylamino)-.alpha.-L-glucopyranosyl-(1->2)-O-5-deoxy-3-C-formyl-.alpha.-L-lyxofuranosyl-(1->4)-N,N'-bis(aminoiminomethyl)-D-streptamine and Liposome
Click to Show/Hide
|
|||
Molecular Type |
Small molecule
|
|||
Disease | Bacterial infection [ICD-11: 1A00-1C4Z] | Approved | [1] | |
Structure |
![]() |
Click to Download Mol2D MOL |
||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
Formula |
C21H39N7O12
|
|||
PubChem CID | ||||
Canonical SMILES |
CC1C(C(C(O1)OC2C(C(C(C(C2O)O)N=C(N)N)O)N=C(N)N)OC3C(C(C(C(O3)CO)O)O)NC)(C=O)O
|
|||
InChI |
1S/C21H39N7O12/c1-5-21(36,4-30)16(40-17-9(26-2)13(34)10(31)6(3-29)38-17)18(37-5)39-15-8(28-20(24)25)11(32)7(27-19(22)23)12(33)14(15)35/h4-18,26,29,31-36H,3H2,1-2H3,(H4,22,23,27)(H4,24,25,28)/t5-,6-,7+,8-,9-,10-,11+,12-,13-,14+,15+,16-,17-,18-,21+/m0/s1
|
|||
InChIKey |
UCSJYZPVAKXKNQ-HZYVHMACSA-N
|
|||
CAS Number |
CAS 57-92-1
|
|||
ChEBI ID | ||||
TTD Drug ID | ||||
DrugBank ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
Ferutinin | Ferula sinkiangensisK | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) |
Combination Info
![]() |
|||||
Experimental
Result(s) |
The combination of 1 with each antitubercular drug led to mutual enhancement of the antimycobacterial activity with isoniazid and ethionamide, while no such effect was observed with rifampin or streptomycin. | |||||
Sanguinarine | Bocconia frutescens | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [3] | |||||
Detail(s) |
Combination Info
![]() |
|||||
In-vitro Model | Escherichia coli | Microorganism model | Escherichia coli | |||
Klebsiella pneumoniae | Microorganism model | Klebsiella pneumoniae | ||||
Experimental
Result(s) |
Three-drug combination of sanguinarine + EDTA + streptomycin showed synergistic activity against almost all the strains, as well as a strong reduction in the effective doses of sanguinarine, EDTA and streptomycin. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | Staphylococcus 30S ribosomal subunit (Stap-coc pbp2) | Molecule Info | [4] |
